THY1 and colitis: To test this hypothesis, we depleted ILC3s from Rag1−/−Smarca4ΔILC3 mice using α-Thy1 neutralizing antibody.51 Strikingly, colitis was significantly ameliorated upon treatment of α-Thy1 antibody, as indicated by improved histological scores, decreased percentages, and absolute numbers of neutrophils in the large intestine of α-Thy1-treated Rag1−/−Smarca4ΔILC3 mice compared with IgG-treated group (Fig. 4f–i).